股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 和鉑醫藥控股有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | | 增加 / 減少 (-) | | | 0 | | USD | | 0 | | 本月底結存 | | 20,000,000,000 | USD | | 0.000025 USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 FF301 第 1 ...

Group 1 - The actual controller of Weining Health, Zhou Wei, was sentenced to one and a half years in prison and fined 200,000 yuan, while the subsidiary Shenzhen Weining Zhongtian was fined 800,000 yuan [1] - Weining Health claims that this incident will not have a significant adverse impact on its operations, but the involvement of the actual controller raises concerns about corporate governance and reputation [1] - The case highlights weaknesses in internal control and compliance, prompting investors to be cautious about potential governance issues and ripple effects [1] Group 2 - Northeast Pharmaceutical was ordered to pay 16.45 million yuan in damages due to a contract dispute, with the court rejecting other claims for compensation [2] - This ruling represents a substantial financial loss for Northeast Pharmaceutical and exposes vulnerabilities in its internal control and contract management [2] Group 3 - Novo Nordisk's semaglutide sales reached $25.462 billion in the first three quarters, a 24% increase year-on-year, maintaining a slight lead over Eli Lilly's tirzepatide, which generated $24.837 billion in sales [3] - The competition between semaglutide and tirzepatide reflects the significant market demand and innovation in the metabolic disease sector, with both products driving technological advancements and market expansion [3] Group 4 - HAPO Pharma's subsidiary Nona Bio has entered into an evaluation and licensing agreement with Umoja Biopharma to advance multiple CAR-T cell product developments [4] - This partnership enhances the strategic collaboration established in September 2024 and validates the value of HAPO Pharma's core platform technology [4] - The agreement allows HAPO Pharma to alleviate funding pressures by having the partner bear the high costs of subsequent research and commercialization, showcasing the commercial potential of its cutting-edge technology platforms [4]

Major Events - Wangshan Wangshui-B (02630) has set its share price at HKD 33.37, with the Hong Kong public offering receiving a subscription rate of 6,238.42 times [1] - WeRide-W (00800) achieved a subscription rate of 73.44 times for its Hong Kong public offering, raising approximately HKD 2.264 billion from the global offering [1] - Pony.ai-W (02026) had a subscription rate of 15.88 times for its Hong Kong public offering, with a share price set at HKD 139 [1] - Joyson Electronics (00699) saw a subscription rate of 147.67 times for its Hong Kong public offering, with an expected listing date of November 6 [1] - Standard Chartered Group (02888) plans to issue USD 1 billion in fixed-rate reset perpetual subordinated or convertible securities [1] - Crystal Tech Holdings (02228) subsidiary AILUX announced a strategic partnership with Eli Lilly to enhance AI-driven bispecific antibody development [1] - Giant Star Legend (06683) signed a sales contract exceeding HKD 100 million for quadruped robots, accelerating the integration of "IP + Robotics + AI" [1] - HAPO-B (02142) entered into an evaluation and licensing agreement with UMOJA BIOPHARMA [1] Financial Data - Hong Kong Exchanges and Clearing (00388) reported a profit attributable to shareholders of HKD 13.419 billion for the first three quarters, a year-on-year increase of 45%, with both revenue and profit reaching record highs [1] - Fubo Group (03738) experienced a total revenue growth of approximately 27% in the third quarter [1] - Goodbaby International (01086) reported a revenue of approximately HKD 6.42 billion for the first three quarters, reflecting a year-on-year decline of 1.1% [1]

Core Viewpoint - The announcement highlights a strategic partnership between Nona Bio and Umoja Biopharma to advance the development of in vivo CAR-T cell products through the integration of their respective platforms [1][2]. Group 1: Partnership Details - Nona Bio has entered into an evaluation and licensing agreement with Umoja Biopharma to combine their HCAb Harbour Mice platform and NonaCarFxTM platform with Umoja's VivoVecTM platform [1]. - The agreement signifies an expansion of the strategic partnership established in September 2024 [1]. - Nona Bio will receive an upfront payment, potential option payments, and milestone payments related to the discovery and development of collaborative projects [1]. Group 2: Company Profiles - Umoja Biopharma is a clinical-stage biotechnology company focused on developing accessible and effective in vivo CAR-T cell therapies for oncology and autoimmune diseases [2]. - The VivoVecTM gene delivery technology enhances the patient's immune system's ability to combat diseases [2]. - Umoja Biopharma operates an advanced lentiviral vector development and manufacturing facility located in Louisville, Colorado, which supports its core technology [2].

Core Insights - Heptares Therapeutics has entered into an evaluation and licensing agreement with Umoja Biopharma to combine their respective platforms for the development of in vivo CAR-T cell products, marking a deepening of their strategic partnership established in September 2024 [1][2] Company Overview - Umoja Biopharma is a clinical-stage biotechnology company focused on developing more accessible and effective in vivo CAR-T cell therapies for oncology and autoimmune diseases [2] - The company's VivoVec gene delivery technology enhances the patient's immune system's ability to combat diseases, supported by an advanced manufacturing facility located in Louisville, Colorado [2] - Umoja Biopharma aims to improve the accessibility and effectiveness of immunotherapies, helping more patients lead better and fuller lives [2]

根据协议条款，诺纳生物将有权获得首付款、潜在选择权付款，以及合作项目发现及开发相关里程碑付 款。Umoja Biopharma将负责所有后续产品的开发和商业化工作。 Umoja Biopharma, Inc.是一家处于临床阶段的生物技术公司，致力于在肿瘤和自身免疫性疾病领域开发 更具可及性和有效性的体内CAR-T细胞疗法。Umoja Biopharma的VivoVec体内基因递送技术可增强患者 自身免疫系统对抗疾病的能力。支持其核心技术的是该公司位于美国科罗拉多州路易斯维尔的先进慢病 毒载体开发和制造工厂。Umoja Biopharma相信，其科学研究可以提高免疫疗法的可及性和有效性，帮 助更多患者享有更美好、更充实的生活。 智通财经APP讯，和铂医药-B(02142)发布公告，本公司全资子公司诺纳生物(苏州)有限公司(诺纳生物) 已与Umoja Biopharma, Inc.(Umoja Biopharma)订立评估与授权协议(协议)，旨在将诺纳生物的HCAb Harbour Mice平台和NonaCarFx平台与Umoja Biopharma的VivoVec平台相结合，共同推进多款体内CAR- T细胞产品 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 和鉑醫藥控股有限公司 HBM Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：02142） 自願公告 與UMOJA BIOPHARMA訂立評估與授權協議 本公告由和鉑醫藥控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 作出，以告知本公司股東及潛在投資者有關本集團的最新業務更新。 本公司董事會（「董事會」）欣然宣佈，本公司全資子公司諾納生物（蘇州）有限公司 （「諾納生物」）已與Umoja Biopharma, Inc.（「Umoja Biopharma」）訂立評估與授權 協議（「協議」），旨在將諾納生物的HCAb Harbour Mice®平台和NonaCarFxTM平台 與Umoja Biopharma的VivoVecTM平台相結合，共同推進多款體內CAR-T細胞產品 研發。協議標誌著兩家公司於2024年9月建立的戰略合作夥伴關係進一步深化拓 展。 根據協議 ...

Summary of Key Points Core Viewpoint - On November 4, 38 Hong Kong-listed companies conducted share buybacks, totaling 62.68 million shares and an aggregate amount of HKD 294 million [1][2]. Group 1: Buyback Details - China Feihe repurchased 18 million shares for HKD 76.11 million, with a highest price of HKD 4.260 and a lowest price of HKD 4.210, bringing its total buyback amount for the year to HKD 233 million [1][2]. - COSCO Shipping Holdings repurchased 4.5 million shares for HKD 61.70 million, with a highest price of HKD 13.960 and a lowest price of HKD 13.600, accumulating a total buyback amount of HKD 45.30 billion for the year [1][2]. - Pacific Shipping repurchased 10 million shares for HKD 26.09 million, with a highest price of HKD 2.640 and a lowest price of HKD 2.580, totaling HKD 22.91 million in buybacks for the year [1][2]. Group 2: Notable Companies - The largest buyback amount on November 4 was by China Feihe at HKD 76.11 million, followed by COSCO Shipping Holdings at HKD 61.70 million [1][2]. - In terms of share quantity, China Feihe led with 18 million shares repurchased, followed by Pacific Shipping with 10 million shares and Sinopec with 5.15 million shares [1][2]. - Noteworthy is that companies like Fenbi and Taimei Medical Technology conducted their first buybacks of the year on this date [2].

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan, indicating confidence in its financial position and future prospects [1] Group 1 - The company will repurchase 200,000 shares [1] - The total expenditure for the buyback is HKD 2.5849 million [1] - The buyback is scheduled for November 4, 2025 [1]

Core Viewpoint - Heptagon Pharmaceuticals-B (02142.HK) announced a share buyback of 200,000 shares at a cost of HKD 2.58 million on November 4 [1] Group 1 - The company executed a buyback program, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was HKD 2.58 million, reflecting the company's financial strategy [1] - The number of shares repurchased was 200,000, which may influence the stock's market performance [1]